Investigating how fecal microbiota transplantation can eliminate drug-resistant infections
Temporal dynamics of MDRO eradication after FMT
This study is looking at how a treatment called fecal microbiota transplantation (FMT) might help get rid of stubborn germs in the gut that don't respond to many antibiotics, and if you join, you'll help us learn more about how the bacteria in your intestines can affect antibiotic resistance.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10598519 on NIH RePORTER |
What this research studies
This research explores the use of fecal microbiota transplantation (FMT) as a potential treatment to eradicate multidrug-resistant organisms (MDROs) from the intestines. By analyzing patient samples from a clinical trial, the study aims to understand the mechanisms behind FMT's effectiveness in reducing MDRO colonization. The research will employ advanced techniques such as metagenomic sequencing to assess the changes in bacterial and viral populations following FMT. Patients participating in this research may contribute to a better understanding of how gut microbiota can influence antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by multidrug-resistant organisms who may benefit from fecal microbiota transplantation.
Not a fit: Patients who do not have infections caused by multidrug-resistant organisms or those who are not suitable candidates for fecal microbiota transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic approach to combat multidrug-resistant infections, improving patient outcomes.
How similar studies have performed: Previous small studies have shown promise in using fecal microbiota transplantation to eliminate antibiotic-resistant infections, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Woodworth, Michael Holmes — Emory University
- Study coordinator: Woodworth, Michael Holmes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.